Novartis shares fall after weak Q1 hit by Entresto competition

Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top ...

Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down

NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and ...
Drug Store News

⁠Generic competition impacts Novartis’ earnings

Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on ​Novartis to offset those lost sales with newer drugs or dealmaking, the report said.

Novartis slips as U.S. generic erosion weighs on Q1 results

Novartis Q1 2026 earnings missed as generic competition hit Entresto sales; Kisqali and Pluvicto growth offsets.
Yahoo

Novartis loses initial bid to block generic of best-selling heart drug

(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according ...
pharmaphorum

Novartis shares fall as Entresto sales weaken

Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...
Seeking Alpha

Federal court temporarily blocks generic Entresto: report

The launch of a generic version of Novartis's (NYSE:NVS) blockbuster cardiac drug Entresto has reportedly been temporarily blocked by a federal appeals court as it considers the drugmaker's ...
Drug Store News

Novartis loses initial bid to block MSN's generic Entresto

Novartis was unsuccessful in convincing a federal court to block MSN Pharmaceuticals from introducing its own version of Novartis' heart-failure drug Entresto, according to a court decision issued ...